Fortress Biotech
FBIO
46 hedge funds and large institutions have $7.66M invested in Fortress Biotech in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 9 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 11
0.34% more ownership
Funds ownership: 17.45% → 17.79% (+0.34%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 53 → 46 (-7)
22% less capital invested
Capital invested by funds: $9.77M → $7.66M (-$2.11M)
56% less call options, than puts
Call options by funds: $130K | Put options by funds: $297K
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$353K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$225K |
| 3 |
PAM
PVG Asset Management
Golden,
Colorado
|
+$151K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$141K |
| 5 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$287K |
| 2 |
Renaissance Technologies
New York
|
-$253K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$167K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$122K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$104K |
FBIO Hedge Fund Activity: Q1 2025 in Review
46 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q1 2025, worth a combined $7.66M — down 22% from $9.77M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of FBIO and 2 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 19 added.
The largest buyer was Nantahala Capital Management, adding an estimated $353K. The largest seller was Citadel Advisors, cutting an estimated $287K.
- 46 institutional investors held Fortress Biotech (FBIO) as of Q1 2025, down from 53 in Q4 2024.
- Funds reported $7.66M of Fortress Biotech stock for Q1 2025, down 22% quarter-over-quarter.
- 2 funds opened new Fortress Biotech positions in Q1 2025 and 9 closed out, a net change of -7 holders.
- The largest Fortress Biotech buyer in Q1 2025 was Nantahala Capital Management, an estimated $353K added.
- The largest Fortress Biotech seller in Q1 2025 was Citadel Advisors, an estimated $287K sold.
Based on aggregated 13F filings for Q1 2025.